ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

リコンビナントタンパク質

ACROBiosystems社 プロダクトリスト:Recombinant Protein

サプライヤー
AcroBioSystems
カタログNo.
CD6-H82F5
製品名称
Biotinylated Human B7-2 / CD86 Protein, Fc,Avitag?, premium grade
タンパク質名
B7-2
Species
Human
HOST
HEK293
200ug: 425600円
お問い合わせ
25ug: 103040円
お問い合わせ

Overview

Synonyms -
Characteristics This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag?). The protein has a calculated MW of 53.8 kDa. The protein migrates as 66-90 kDa under reducing (R) condition, and 130-150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level 0.01 EU per μg
Purity 95%
Description Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.
Reference -
URL https://www.acrobiosystems.com/P2193-Biotinylated-Human-B7-2--CD86-Protein-FcAvitag%E2%84%A2-premium-grade.html

お問い合わせリスト(-)

お問い合わせフォーム